Aesthetics

Safety, Tolerability, and Efficacy of Repeat-Dose Injections of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results from a Prospective, Open-Label, Phase III Study

By April 29, 2020No Comments

Dermatology News

"Safety, Tolerability, and Efficacy of Repeat-Dose Injections of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results from a Prospective, Open-Label, Phase III Study"

IncobotulinumtoxinA (Xeomin/Xeomeen/Bocouture/XEOMIN Cosmetic; botulinum toxin type A free from complexing proteins [150 kDa]; Merz Pharmaceuticals GmbH) is indicated worldwide for the correction of glabellar frown lines (GFL) and in Europe additionally for lateral periorbital lines (LPL; crow’s feet) and upper facial lines (UFL; ie, simultaneous treatment of GFL, LPL, and horizontal forehead lines [HFL]).1

The efficacy of incobotulinumtoxinA in the treatment of multiple or singular facial areas has been extensively demonstrated.2-10 With the recent surge in interest for a more holistic approach, consisting of combined treatment of GFL, HFL, and LPL in a single treatment session, there is a need for demonstrating safety and efficacy for such procedures.

This study provides strong evidence for the safety and tolerability of repeat-dose treatments with incobotulinumtoxinA in UFL (GFL, 20 U; HFL, 10-20 U; LPL, 24 U). A stable safety profile was demonstrated during prolonged administration and a noteworthy trend to better tolerability with continued use of incobotulinumtoxinA was established

Read More

You May Also Like

JDD in the News: Pharmacy Deserts and Affordability Concerns in Atopic Dermatitis Care

| Atopic Dermatitis, Featured Articles, JDD Highlights, JDD in the Media, The Latest | No Comments
Healio profiled a July Journal of Drugs in Dermatology study on the affordability of dermatologist-recommended skincare products for atopic dermatitis. The study, “Socioeconomic Disparities in Gentle Skin Care Access for…

New Innovations with SkinCeuticals: A.G.E. Interrupter Ultra Serum

| JDD Highlights, JDD Webinars, The Latest | No Comments
Active ingredients play a critical role in the efficacy and safety of cosmeceuticals. Join Julie Ann Woodward, MD as she shares information on the efficacy and safety on a new…

Acneceuticals: Maximizing Therapeutic Outcomes​ in Acne Treatment

| JDD Highlights, JDD Webinars, The Latest | No Comments
A New US Consensus on Acneceuticals in the Management of Acne Vulgaris: From Concept to Clinical Practice Faculty Hilary Baldwin, MD Board-Certified Dermatologist Medical Director Acne Treatment & Research Center…

Leave a Reply